Clinical Hepatology Update On-Demand 2019

5 (5 votes)

Recorded On: 06/14/2019

The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

Core Competencies:  Patient Care and Procedural Skills Provide Patient-centered Care Values/Ethics for Interprofessional Practice Medical Knowledge Work in Interdisciplinary Teams Roles/Responsibilities Practice-based Learning and Improvement Employ Evidence-based Practice Interprofessional Communication Interpersonal and Communication Skills Apply Quality Improvement Teams and Teamwork Systems-based Practice

Program Chairs:  Marcelo Kugelmas, MD, FAASLD Elizabeth K. Goacher, PA-C, MHS Janice Jou, MD, MHS  Lisa Catalli, MSN, NP-B

CME Hours: 13.00 AMA PRA Category 1 Credits

MOC Points: 13.00 MOC Points 

Continuing Education (Nursing Credits): 13.00 Contact Hours

Pharmacology: 1.25 Pharmacology Credits 

All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

Release Date: July 31, 2019
Expiration Date: July 30, 2021


Copyright: All faculty in this activity have given their permission for publication OR ©2019 AASLD

Key:

Complete
Failed
Available
Locked
Session I: NASH
Liver Biopsies for Everyone? Diagnostic Dilemma in the Epidemic - Fibrosis Assessment and Risk Stratification
Open to view video.
Open to view video. Kathleen E. Corey, MD, MPH, MMSc
Nonalcoholic Fatty Liver Disease: Current State of Care Management
Open to view video.
Open to view video. Sonali Paul, MD
NASH as a Team Sport: Multidisciplinary Management, Successful Examples/Best Practices
Open to view video.
Open to view video. Michael F. Chang, MD, MSc, MBA, FAASLD
NASH is More than BMI: Prevalence and Impact of Lean NASH
Open to view video.
Open to view video. Anne M. Larson, MD, FAASLD
Quiz
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Session II: Portal Hypertension
Non-cirrhotic Portal Hypertension
Open to view video.
Open to view video. Willscott E. Naugler, MD, FAASLD
The Expanding Role of TIPS
Open to view video.
Open to view video. Khashayar Farsad, MD, PhD
Gastric Variceal Bleed Management: BRTO Primer, Glue
Open to view video.
Open to view video. Bryan L. Balmadrid, MD
Anticoagulation in Portal Hypertension: Who, When, How, and for How Long?
Open to view video.
Open to view video. Stephen H. Caldwell, MD, FAASLD
Palliative Interventions: Who, How, What?
Open to view video.
Open to view video. Jody C. Olson, MD
Quiz
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Session III: Lumps and Bumps in the Road
Liver Adenomas, Management According to Size, Location, Symptoms and Genetics
Open to view video.
Open to view video. K. Rajender Reddy, MD, FAASLD
Immunotherapies for HCC: What the Hepatologist Needs to Know
Open to view video.
Open to view video. Catherine T. Frenette, MD
The Changing Landscape of HCC Management
Open to view video.
Open to view video. Janice Jou, MD, MHS
Clinical Pearls for Less Common Liver Diseases
Open to view video.
Open to view video. Michael F. Chang, MD, MSc, MBA, FAASLD
Quiz
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Session IV: Everything But NASH
HBV Diagnostics: Anything New
Open to view video.
Open to view video. Robert G. Gish, MD, FAASLD
Autoimmune Hepatitis: When to Change and When/IF to Stop Therapy
Open to view video.
Open to view video. Marcelo Kugelmas, MD, FAASLD
Pearls in the Management of PBC and PSC
Open to view video.
Open to view video. Cynthia Levy, MD, FAASLD
It’s All About the Microbiome: A State-of-the-Art Lecture
Open to view video.
Open to view video. Jasmojan S. Bajaj, MD, FAASLD
Quiz
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Session V: Nutrition, Frailty and Palliative Care
Quality of Care in Cirrhosis
Open to view video.
Open to view video. Elliot B.Tapper, MD
Frailty: Impact of Sarcopenia and Overcoming Management Challenges
Open to view video.
Open to view video. Jennifer C. Lai, MD, MBA
Practical Tips for Closing the “Know-Do Gap” to Enhance Nutrition in the Lives of Patients with Cirrhosis
Open to view video.
Open to view video. Punetta Tandon, MD, FRCPC
Palliative Care: When to Refer
Open to view video.
Open to view video. Arpan Patel, MD
Quiz
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Session VI: Hepatology Practice Outside of the Hepatology Clinic
Liver Disease in the Pregnant Patient
Open to view video.
Open to view video. Jackie F. Fleckenstein, MD, FAASLD
Hepatology in and Around the OR: Pre-op Risk Assessment and Perioperative Management
Open to view video.
Open to view video. Jody C. Olson, MD
Behavioral Therapy in Liver Disease
Open to view video.
Open to view video. Robert M. Weinrieb, MD
Transplant Medicine Back Home: Pearls for the Non-Transplant Provider
Open to view video.
Open to view video. Michael D. Leise, MD
Controversies of Treating HCV Before or After Liver and or Kidney Transplant
Open to view video.
Open to view video. Richard Gilroy, MD
Quiz
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Final Credits, Certificate, & Evaluation
CE Credits (SELECT ONLY FOR YOUR CREDENTIALS)
13.00 CE Credits credits  |  Certificate available
13.00 CE Credits credits  |  Certificate available
CME Credits (SELECT ONLY FOR YOUR CREDENTIALS)
Up to 13.00 medical credits available  |  Certificate available
Up to 13.00 medical credits available  |  Certificate available You may receive ABIM MOC points, ONLY if you have claimed CME credits for this enduring activity.
ABIM/ABP MOC Points
Up to 13.00 medical credits available  |  Certificate available
Up to 13.00 medical credits available  |  Certificate available Must claim CME in order to receive MOC points.
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.

Upon completion of this activity, learners will be able to: 

To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
Manage patients with complications of portal hypertension.
Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Physician Assistants
Transplant Coordinators
Fellows/Trainees 

Jasmohan Bajaj, MD, FAASLD
Bryan Balmadrid, MD
Stephen Caldwell, MD, FAASLD
Lisa Catalli, MSN, NP-BC
Michael Chang, MD, MSc, MBA, FAASLD
Kathleen Corey, MD, MPH, MMSc
Khashayar Farsad, MD
Jaquelyn Fleckenstein, MD, FAASLD
Catherine Frenette, MD
Richard Gilroy, MD
Robert Gish, MD, FAASLD
Elizabeth Goacher, PA-C, MHS
Janice Jou, MD, MHS
Marcelo Kugelmas, MD, FAASLD
Jennifer Lai, MD
Anne Larson, MD, FAASLD
Michael Leise, MD
Cynthia Levy, MD, FAASLD
Willscott Naugler, MD, FAASLD
Jody Olson, MD
Arpan Patel, MD
Sonali Paul, MD
K Rajender Reddy, MD, FAASLD
Puneeta Tandon, MD, FRCPC
Elliot Tapper, MD
Robert Weinrieb, MD

Disclosures

This enduring educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Clinical Hepatology Update faculty and the Clinical Research Committee and Governing Board.

As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.

Faculty Disclosures
Jasmohan Bajaj, MD, FAASLD       
Advisory Board and/or Committee and Review Panels: Valeant, Norgine, Intercept
Honoraria for CME Activities: Integrity CE. CLD communications
Grants/Research Support: Valeant 

Bryan Balmadrid, MD          
Nothing to disclose

Stephen Caldwell, MD, FAASLD    
Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed, Vital Therapy

Lisa Catalli, MSN, NP-BC    
Nothing to disclose 

Michael Chang, MD, MSc, MBA, FAASLD 
Nothing to disclose 

Kathleen Corey, MD, MPH, MMSc  
Speaking and Teaching: Synageva
Scientific Consulting: Novo Nordisk

Khashayar Farsad, MD        
Scientific Consulting: Cook Medical, Neuwave Medical 
Grants/Research Support: Guerbet, LLC Leadership in related society: American Society of Digestive Disease Interventions (consensus panel committee) 

Jaquelyn Fleckenstein, MD, FAASLD       
Nothing to disclose

Catherine Frenette, MD       
Scientific Consulting: Bayer, Intercept; Speakers Bureau: Bayer, Gilead

Richard Gilroy, MD  
Speakers Bureau: Novartis, Gilead, Salix

Robert Gish, MD, FAASLD  
Scientific Consulting: Abbot, AbbVie, Alexion, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Contravir, Eiger, Enyo, eStudySite, Genentech, Gilead Sciences, HepaTX, HepQuant, Hoffmann-LaRoche Ltd., Intellia, Intercept, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi, Transgene
Trimaran Leadership in related society: AbbVie, Merck, Arrowhead, Bayer, Contravir, Dova Pharmaceuticals, Eiger, Enyo, Janssen, Medimmune, Janssen/J&J, Intercept, Shionogi, Spring Bank, Ionis
Speakers Bureau: Alexion, Bayer, BMS, Dova, Gilead Sciences Inc., AbbVie, Merck

Elizabeth Goacher, PA-C, MHS      
Scientific Consulting: Gilead Pharmaceuticals, AbbVie Pharmaceuticals
Speakers Bureau: AbbVie Pharmaceticals, Gilead Pharmaceuticals

Janice Jou, MD, MHS          
Nothing to disclose

Marcelo Kugelmas, MD, FAASLD  
Speakers Bureau: Intercept, Dova, Merck, Gilead, Abbvie, Salix
Scientific Consulting: Gilead, Abbvie, Merck, Salix, Shinogi, Dova, Intercept, Mallinkrodt 
Grants/Research Support: Novartis, Enanta, Tobira, Pfizer, Madrigal, Genfit, Shire, Cirius, Intercept, Dova, Gilead

Jennifer Lai, MD       
Scientific Consulting: Third Rock Ventures, LLC, Axcella

Anne Larson, MD, FAASLD
Nothing to disclose

Michael Leise, MD    
Nothing to disclose

Cynthia Levy, MD, FAASLD
Grants/Research Support: Intercept, Gilead, GSK, Novartis, Genfit, CymaBay, Enanta, Arena, Durect, High Tide, Eli Lilly
Scientific Consulting: Target Pharma Solutions, Pliant, Cara Therapeutics
Leadership in related society: Associate Editor- Liver Transplantation

Willscott Naugler, MD, FAASLD     
Nothing to disclose 

Jody Olson, MD       
Nothing to disclose 

Arpan Patel, MD       
Nothing to disclose

Sonali Paul, MD        
Nothing to disclose 

K Rajender Reddy, MD, FAASLD   
Grant/Research Support: AbbVie,Gilead, Janssen, Merck, Intercept, Mallinckrodt, Conatus, Novartis 

Puneeta Tandon, MD, FRCPC        
Advisory Committee and/or Review Panels: Lupin Pharma Canada 

Elliot Tapper, MD     
Grants/Research Support: Valeant, Gilead
Scientific Consulting: Novartis

Robert Weinrieb, MD           
Nothing to disclose

Planning Committee Disclosures
Curtis K. Argo, MD, MS, FAASLD (Maintenance of Certification Committee)
Nothing to disclose 

Meena B. Bansal, MD, FAASLD (Governing Board)
Nothing to disclose 

Jorge A. Bezerra, MD, FAASLD (Governing Board)
Grant/Research Support: Shyer, Gilead 

Mamatha Bhat (Clinical Research Committee)
Nothing to disclose 

Therese Bittermann, MD (Clinical Research Committee)
Nothing to disclose

Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
Nothing to disclose

Raymond Chung, MD, FAASLD (Governing Board; Maintenance of Certification Committee)
Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
Other: DSMB – Alnylam

Laurie DeLeve, MD, PhD, FAASLD (Governing Board) 
Consulting: Daiichi Sankyo; Seagen; Pfizer

Edward Doo, MD (Clinical Research Committee) 
Nothing to disclose

Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
Grants/Research Support: BMS, Gilead, Abbvie
Consulting: Sanofi

Kimberly A Forde, MD, MHS (Clinical Research Committee)
Nothing to disclose 

Michael W. Fried, MD, FAASLD (Governing Board)
Stock/Stock Options: TARGET PharmaSolutions Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health

Debra Guss, DNP, RN, ANP-C (Maintenance of Certification Committee)
Nothing to disclose

Steven K. Herrine, MD, FAASLD (Maintenance of Certification Committee)
Grant/Research Support: Gilead, BMS, Galectin, Intercept

Vandana Khungar, MD, MSc (Maintenance of Certification Committee)
Nothing to disclose

Ayman A. Koteish, MD, FAASLD (Maintenance of Certification Committee)
Nothing to disclose

Paul Yien Kwo, MD, FAASLD (Clinical Research Committee) 
Consulting: Gilead, Abbvie Grants/Research Support: BMS, Abbvie 

John R. Lake, MD, FAASLD (Governing Board)
Consulting: Vital Therapies, SRTR
Other: Intercept DSMB

Jennifer Cindy Lai, MD (Clinical Research Committee)
Consulting: Third Rock Ventures, LLC, Axcella

Rohit Loomba, MD (Clinical Research Committee)
Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc

Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
Board Membership: ACG Research Committee, Baxalta, DSMB
Consulting: National Hemophilia Foundation 

Lopa Mishra, MD, FAASLD (Governing Board)
Grant/Research Support: NIH 

Smruti R. Mohanty, MD, MS (Maintenance of Certification Committee)
Leadership in related society: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World journal of hepatology
Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept 

David C. Mulligan, MD, FAASLD (Governing Board)
Nothing to disclose 

Arpan A. Patel, MD (Clinical Research Committee) 
Nothing to disclose

Heather M. Patton, MD, FAASLD (Maintenance of Certification Committee) 
Grant/Research Support: Gilead Sciences 

K. Gautham Reddy, MD, FAASLD (Maintenance of Certification Committee) 
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
Speaker's Bureau: Intercept Dova;
Research Grants: Merck Intercept Genfit 
Scientific Consulting:  Advisor to Industry Commercial Enterprise, including Development of Educational Presentations: Intercept

Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
Nothing to disclose

Ronald J. Sokol, MD, FAASLD (Governing Board)
Consulting: Alexion; Albireo; Retrophin; Shire Grant/Research Support: Lumena/Shire; FFF Enterprises 

Grace L. Su, MD, FAASLD (Maintenance of Certification Committee)
Company Employee, Officer, Director: My husband and son have equity interest in Applied Morphomics and Prenovo

Shikha Sundaram, MD, MSCI (Clinical Research Committee)
Nothing to disclose

Ryan M. Taylor, MD (Maintenance of Certification Committee)
Speaker's Bureau: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Merck, Inc., Abbvie, Inc.
Grant/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie, Conatus Pharmaceuticals 

Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
Advisory Committees and/or Review Panels: Dova
Grant/Research Support: AbbVie, Gilead, BMS, Merck 

Kymberly Watt, MD (Clinical Research Committee)
Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related

Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals

Staff Disclosures
Dominique Clayton 
Nothing to disclose

Katie Duggan, BA
Nothing to disclose

Janeil Klett
Nothing to disclose

Denise Seise
Nothing to disclose

Anne Wrobel 
Nothing to Disclose 


Acknowledgement of Financial or In-Kind Commercial Support

No financial or in-kind commercial support was received for this educational activity.

Satisfactory completion 

Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

Credits Offered Continuing Medical Education (CME): 13.00 AMA PRA Category 1 Credits™ Maintenance of Certification (MOC): 13.00 MOC Points Continuing Education (CE): 13.00 Contact Hours Pharmacology: 1.25 Pharmacology Credits

Accreditation and Designation Statements

Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Pharmacology Credits  The following presentations are also eligible for 1.25 pharmacotherapeutic hours:

The Other Side of the Triad: Non-Cirrhotic Portal Hypertension Anticoagulation in Portal Hypertension Back to the Basics: Hepatitis B Management AIH: When to Change and If/When to Stop Therapy

Please note onsite documentation for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board. Keep the agenda as a reference in case they have questions.

Claiming CME Credits Physicians and other health care professionals seeking 13.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by Friday, July 30, 2021

Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by Friday, July 30, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM and ABP by the end of each month through August 2021 for individuals who successfully complete the MOC evaluation.

Claiming CE Contact Hours and Pharmacology Credits
1.    Go to http://aasld.cmecertificateonline.com
2.    Click on the “2019 Clinical Hepatology Update” link  
Please print all pages of your certificate for your record.
Questions? Email Certificate@AmedcoEmail.com